ABSTRACT
Over the past few years, intravenous immunoglobulin (IVIG) has become an impor tant treatment option for various autoimmunerelated neurological diseases^1-3! Efficacy equalling that of plasmapheresis has been con vincingly documented in Guillain-Barre syn drome and in chronic inflammatory demyelinating polyneuropathy J3-5! Although myasthenia gravis has been less extensively studied, some have similar views in regard to treating a myasthenic crisis,^ and in multifocal motor neuropathy, the benefits of IVIG (although limited) have to be weighed against quite aggres sive therapies such as cyclophosphamide.^ In all these examples, the ease of administration, good tolerability and a reasonable safety profile are factors that are cited in favour of IVIG. These possible advantages over alternative immunomodulating therapies may also be of interest for patients suffering from other neuro logical autoimmune disorders such as multiple sclerosis (MS).
